Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Trading Up 0.6 %

NYSE:SENS opened at $0.48 on Thursday. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The company’s 50 day moving average is $0.34 and its 200-day moving average is $0.38. The firm has a market cap of $283.26 million, a price-to-earnings ratio of -3.66 and a beta of 0.77. Senseonics has a 12 month low of $0.25 and a 12 month high of $0.75.

Insider Buying and Selling at Senseonics

In other news, CEO Timothy T. Goodnow bought 315,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the completion of the transaction, the chief executive officer now directly owns 11,310,355 shares in the company, valued at $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

Several institutional investors have recently modified their holdings of SENS. FMR LLC lifted its holdings in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after acquiring an additional 167,970 shares during the period. GSA Capital Partners LLP bought a new stake in Senseonics in the third quarter valued at about $117,000. Symmetry Partners LLC acquired a new position in Senseonics in the third quarter worth about $164,000. Cubist Systematic Strategies LLC lifted its stake in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares in the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.